Skip to content
FCF Fox Corporate Finance GmbH
FCF Fox Corporate Finance GmbH
  • About FCF
    • Business
    • Team
    • History
    • Facts
    • Philosophy
  • Business Units
    • FCF MidCap
    • FCF DeepTech
    • FCF Healthcare & Life Sciences
  • References
    • Testimonials
    • Transactions
  • Research
    • FCF MidCap Market Research
      • FCF Interest & Corporate Loan Monitor
      • FCF Valuation Monitor
      • FCF Bank Monitor
      • FCF Sector Monitor
    • FCF DeepTech Research
      • FCF Robotics Venture Capital Report
      • FCF CleanTech Venture Capital Report
      • FCF Advanced Manufacturing Venture Capital Report
      • FCF IoT Venture Capital Report
    • FCF Healthcare & Life Sciences Research
      • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe
      • FCF Healthcare & Life Sciences Venture Capital Monitor – USA
  • Career
  • Contact
FCF Fox Corporate Finance GmbH
  • About FCF
    • Business
    • Team
    • History
    • Facts
    • Philosophy
  • Business Units
    • FCF MidCap
    • FCF DeepTech
    • FCF Healthcare & Life Sciences
  • References
    • Testimonials
    • Transactions
  • Research
    • FCF MidCap Market Research
      • FCF Interest & Corporate Loan Monitor
      • FCF Valuation Monitor
      • FCF Bank Monitor
      • FCF Sector Monitor
    • FCF DeepTech Research
      • FCF Robotics Venture Capital Report
      • FCF CleanTech Venture Capital Report
      • FCF Advanced Manufacturing Venture Capital Report
      • FCF IoT Venture Capital Report
    • FCF Healthcare & Life Sciences Research
      • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe
      • FCF Healthcare & Life Sciences Venture Capital Monitor – USA
  • Career
  • Contact

Blog

Venture capital funding in 2022 significantly decreased compared to 2021

The ever-increasing venture capital funding for European life sciences companies halted in 2022. With a roughly EUR 9.6bn volume, the overall financing for European life sciences companies in 2022 decreased significantly compared to 2021 (EUR … Read more

European VC life sciences funding continues to decline

In 2022, the venture capital funding for life sciences in Europe continues to weaken, further widening the gap to 2021 (EUR 9.4bn vs. EUR 6.5bn). The cumulative financing volume in August 2022 falls by more … Read more

US year-to-date funding volume now below previous year’s level

After an exceptional year 2021 for venture capital funding in the US Biotech-sector, aggregated financing volumes in 2022 are for the first time lower than in 2021. During the last months funding volumes have declined … Read more

Overall negative Life Sciences Sentiments recorded in August 2022

The FCF Life Sciences team continuously analyses the current sentiments in the European life sciences venture capital funding sector. For August ’22, venture capital funding continues to decline. All life sciences subsectors (i.e. Biotech, HealthTech, … Read more

AgriTech sector on the rise with venture financing at record levels

Transaction volumes and the number of closed deals in the AgriTech space continued their steady growth in the US and massively surged in Europe. In the US, VC financing volumes in AgriTech more than doubled … Read more

Longevity on the rise – Constant growth in the US and its arrival in Europe

2022-08-09 - IOTW - Longevity

The significant growth of transaction volumes and the number of deals closed from 2017 to 2021 confirms the increasing importance of longevity in the US and Europe. For both markets, the number of deals almost … Read more

Funding for Genomics exceeds all other subsectors in the ‘OMX-space

Genomics-Funding-Volume.

Genomics represents the most crucial pillar in the ‘OMX-space and is the largest subsector in the US and Europe (EUR 13.3bn vs. EUR 1.8bn). The second and third largest subsectors are microbiomics and proteomics for … Read more

A continued downward spiral of financing volumes for life sciences in the US

IOTW-Comparison-of-Investment-Volumes-First-Half-of-the-Year-US

A recent FCF Life Sciences analysis showed a significant decline in funding volumes for European life sciences markets in the first half of 2022 compared to 2021. This trend is now confirmed for the US … Read more

Significant decline of financing volumes for life sciences across all stages in Europe

Comparison-of-Life-Sciences-Investment-Volumes-First-Half-of-the-Year

During the first six months of 2022, we find that the funding for life sciences markets declined significantly compared to 2021. The trend affects all relevant life sciences subsectors of Biotech, HealthTech, and MedTech. The … Read more

Significant cooldown of venture capital financing for European life sciences markets

Sentiment_cooldown

Venture capital deal volumes in the European life sciences sector reached a record-breaking level in 2021. However, financing volumes decreased significantly by 29% in the first four months of 2022 compared to 2021.   Our … Read more

Older posts
Page1 Page2 … Page5 Next →

Unsere letzten Beiträge

  • FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 04/2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 04/2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 03/2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 03/2025 published
  • FCF Bank Monitor – Q1 2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 02/2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 02/2025 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 01/2025 published
  • FCF Interest & Corporate Loan Monitor Q4/2024 published
  • FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – 12/2024 published
FCF Fox Corporate Finance GmbH • Maximilianstr. 12-14 • 80539 Munich, Germany • T: +49-89-20 60 409-0 • Imprint • Data Protection • LinkedIn • Xing
Scroll Up